Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
University of Cologne
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
26Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03516214CT.gov EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bronchial Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nazartinib (this asset) | University of Cologne | P1 | CC · 41 |
| Carboplatin | Nanfang Hospital, Southern Medical University | P3 | BB |
| Docetaxel | University of Turin, Italy | P3 | B |
| Vinorelbine Ditartrate | University of Turin, Italy | P3 | B |
| Icotinib | Sun Yat-sen University | P2 | CCC |
| Nivolumab | University of Colorado, Denver | P2 | CCC |
| Etoposide | Nanfang Hospital, Southern Medical University | P2 | CCC |
| Alectinib | Hoffmann-La Roche | P2 | CCC |
| Adebrelimab | Nanfang Hospital, Southern Medical University | P2 | CCC |
+9 more in the Bronchial Neoplasm cohort
Other indications for Nazartinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cutaneous Melanoma | — | P2 | CCC · 49 |
| Non-Small Cell Lung Carcinoma | — | P2 | CC · 46 |
| Lung Cancer | — | P2 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nazartinib in Bronchial Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nazartinib-bronchial-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →